Purdue Pharma Signs an Agreement with Alivio Therapeutics for its ALV-107

 Purdue Pharma Signs an Agreement with Alivio Therapeutics for its ALV-107

Purdue Pharma Signs an Agreement with Alivio Therapeutics for its ALV-107

Shots:

  • Alivio to receive $14.75M upfront, $260M milestones, license exercise payments and royalties on sales of product from Purdue. Purdue to get an option to add more compounds to the agreement based on Alivio’s inflammation-targeting technology, including an option for equity investment in Alivio
  • The company received funding of $3.3M from the US DOD Technology/Therapeutic Development for its ALV-107 program, to further evaluate it in trials including GMP manufacturing and its IND filing
  • ALV-107 is a non-opioid treatment based on Alivio’s inflammation-targeting technology, targeted for interstitial cystitis/bladder pain syndrome (IC/BPS) and has shown the reduction in pain in clinical trials

 Click here to read full press release/ article | Ref: Alivio Therapeutics | Image: Alivio Therapeutics

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post